TOKYO, May 14 (Pulse News Wire) – Adr120s,inc. (3750.T) signed a joint research agreement with Tokyo Medical University to develop Neocella, a product containing cell-derived components and extracellular particles.
The collaboration aims to evaluate Neocella's biological functions, mechanisms of action, and potential applications in human and animal fields, focusing particularly on inflammatory diseases such as endometritis. Under the agreement, ADR Therapeutics, a subsidiary of ADR120S, will work closely with Professor Takahiro Otani from Tokyo Medical University’s Molecular and Cellular Therapy Research Department. Key areas of focus include assessing Neocella’s biological functionality, analyzing its mechanism of action and intercellular communication, and developing stable manufacturing processes.
Tokyo Medical University was established in 1916 and is located in Shinjuku, Tokyo. It is recognized globally for pioneering research in exosomes and extracellular vesicles, contributing significantly to cancer studies, regenerative medicine, diagnostics, and drug discovery. Looking ahead, ADR120S plans to leverage this partnership to advance long-term research and development strategies in regenerative medicine and biotechnology.
The company intends to continue fostering collaborations with academic institutions to drive innovation in extracellular particle technology and regenerative medical applications.
🟢 Confidence: High AI-translated content.